Andere talen Ionis Pharmaceuticals, Inc.

Aandelen

IONS

US4622221004

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
42,45 ^USD	+1,46%		+3,76%	-16,09%

10/04	IONIS PHARMACEUTICALS, INC. : Wolfe Research herziet advies naar Kopen	ZM
09/04	IONIS PHARMACEUTICALS, INC. : Oppenheimer handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ionis Publishes 2023 Corporate Responsibility Report	13:01
Ionis to hold first quarter 2024 financial results webcast	23/04
North American Morning Briefing : Stock Futures -2-	11/04
North American Morning Briefing : Traders Await -2-	10/04
Ionis Pharmaceuticals : Listen to webcast	09/04
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome	08/04
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	07/04
Ionis to present at upcoming investor conferences	01/04
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting	26/03
Sector Update: Health Care Stocks Gain Premarket Wednesday	13/03
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up	13/03
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	13/03
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH	13/03
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	13/03
Ionis Pharmaceuticals, Inc. Announces Executive Changes	29/02
Ionis announces new chief global product strategy officer to lead next phase of commercial growth	29/02
Ionis to present at upcoming investor conferences	28/02
Travere drug for rare kidney condition recommended for EU approval	23/02
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	21/02
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	21/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ionis Pharmaceuticals, Inc.

Aandelen

IONS

US4622221004

Andere talen

Filters